<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02904512</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00070039</org_study_id>
    <nct_id>NCT02904512</nct_id>
  </id_info>
  <brief_title>Inpatient Diabetes Mellitus (DM) Management With Continuous Glucose Monitoring Devices, a Pilot Study.</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DexCom, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Several observational studies have shown that uncontrolled hyperglycemia in hospitalized&#xD;
      patients in the non-critical care, non-Intensive Care Unit (non-ICU) setting is associated&#xD;
      with prolonged length of stay, increased mortality and an increased incidence of infections.&#xD;
      Randomized clinical trials in both the critical and the non-ICU settings have shown that by&#xD;
      improving glucose control there is a decrease in the incidence of infections, length of stay&#xD;
      and inpatient health care costs.&#xD;
&#xD;
      Continuous glucose monitoring (CGM) systems have evolved as useful devices providing&#xD;
      excellent clinical care in patients with Diabetes Mellitus (DM). These systems detect glucose&#xD;
      in subcutaneous interstitial fluid using a glucose sensor that transmits glucose measurements&#xD;
      to a receiving device that reads out average glucose levels every couple of minutes.&#xD;
&#xD;
      In this clinical trial the investigators propose to examine the clinical use of CGM in&#xD;
      hospitalized patients with Diabetes Mellitus type 2 (DM2). CGM use may improve glucometric&#xD;
      values and clinical outcomes in hospitalized individuals with Diabetes Mellitus type 2 (DM2).&#xD;
&#xD;
      We use CGM devices to monitor but also to transmit glucose values wirelessly to monitoring&#xD;
      devices that are in the nursing station. Half of the participants are placed on Real Time CGM&#xD;
      (alarms turned on) and half of them are placed on blinded CGM values (alarms turned off).&#xD;
      Nursing staff will be notified when glucose is &lt;85 mg/dl , in order to treat and potentially&#xD;
      prevent a potential hypoglycemic episode.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Actual">December 22, 2017</completion_date>
  <primary_completion_date type="Actual">December 22, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Time Spent in Hyperglycemia &gt; 180 mg/dL</measure>
    <time_frame>Through study completion, during hospital stay, an average of 1 week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Time Spent in Significant Hyperglycemia (&gt;300 mg/dL)</measure>
    <time_frame>Through study completion, during hospital stay, an average of 1 week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Hypoglycemic Events (&lt; 70mg/dL)</measure>
    <time_frame>Through study completion, during hospital stay, an average of 1 week</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Continuous glucose Monitoring and Point of Care blood glucose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hospitalized patients with Diabetes Mellitus type 2 (DM2) managed with Continuous glucose monitoring (CGM) and Point of Care (POC) Finger sticks blood glucose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Point of Care (POC) blood glucose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Hospitalized Diabetes Mellitus type 2 (DM2) patients managed with Point of Care (POC) blood glucose only</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous glucose Monitoring (CGM) device and Point of Care (POC) blood glucose</intervention_name>
    <description>Testing Blood Glucose levels with Continuous glucose Monitoring (CGM) device and Point of Care (POC) blood glucose</description>
    <arm_group_label>Continuous glucose Monitoring and Point of Care blood glucose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Point of Care (POC) blood glucose</intervention_name>
    <description>Testing Blood Glucose levels with Point of Care (POC) blood glucose</description>
    <arm_group_label>Point of Care (POC) blood glucose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  History of Diabetes Mellitus type 2 (DM2) on insulin&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Patients that are expected to require a hospital stay ≤3 days&#xD;
&#xD;
          -  Pregnant patients&#xD;
&#xD;
          -  Subjects that have significant hyperglycemia or Diabetic Ketoacidosis (DKA) that&#xD;
             requires treatment with intravenous insulin infusion&#xD;
&#xD;
          -  Patients receiving glucocorticosteroids in doses (equivalent) to ≥ 20 mg of&#xD;
             hydrocortisone/day&#xD;
&#xD;
          -  Any mental condition rendering the subject incapable of understanding the objectives&#xD;
             and potential consequences of the study&#xD;
&#xD;
          -  Patients that need hospitalization in the critical care (ICU) setting.&#xD;
&#xD;
          -  History of Diabetes Mellitus type 1 (DM1)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Baltimore VA Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>August 30, 2016</study_first_submitted>
  <study_first_submitted_qc>September 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2016</study_first_posted>
  <results_first_submitted>April 25, 2021</results_first_submitted>
  <results_first_submitted_qc>May 29, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 22, 2021</results_first_posted>
  <last_update_submitted>May 29, 2021</last_update_submitted>
  <last_update_submitted_qc>May 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>Ilias Spanakis</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Only de-identified data are going to be shared.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 25, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT02904512/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Continuous Glucose Monitoring and Point of Care Blood Glucose</title>
          <description>Hospitalized patients with Diabetes Mellitus type 2 (DM2) managed with Continuous glucose monitoring (CGM) and Point of Care (POC) Finger sticks blood glucose&#xD;
Continuous glucose Monitoring (CGM) device and Point of Care (POC) blood glucose: Testing Blood Glucose levels with Continuous glucose Monitoring (CGM) device and Point of Care (POC) blood glucose</description>
        </group>
        <group group_id="P2">
          <title>Point of Care (POC) Blood Glucose</title>
          <description>Hospitalized Diabetes Mellitus type 2 (DM2) patients managed with Point of Care (POC) blood glucose only&#xD;
Point of Care (POC) blood glucose: Testing Blood Glucose levels with Point of Care (POC) blood glucose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Transferred to ICU</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Minor Bleeding at site of device insertion</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Continuous Glucose Monitoring and Point of Care Blood Glucose</title>
          <description>Hospitalized patients with Diabetes Mellitus type 2 (DM2) managed with Continuous glucose monitoring (CGM) and Point of Care (POC) Finger sticks blood glucose&#xD;
Continuous glucose Monitoring (CGM) device and Point of Care (POC) blood glucose: Testing Blood Glucose levels with Continuous glucose Monitoring (CGM) device and Point of Care (POC) blood glucose</description>
        </group>
        <group group_id="B2">
          <title>Point of Care (POC) Blood Glucose</title>
          <description>Hospitalized Diabetes Mellitus type 2 (DM2) patients managed with Point of Care (POC) blood glucose only&#xD;
Point of Care (POC) blood glucose: Testing Blood Glucose levels with Point of Care (POC) blood glucose</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.2" spread="6.4"/>
                    <measurement group_id="B2" value="67.9" spread="9.6"/>
                    <measurement group_id="B3" value="69.1" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.1" spread="9.3"/>
                    <measurement group_id="B2" value="30.9" spread="4.9"/>
                    <measurement group_id="B3" value="32.0" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>A1c, %</title>
          <units>% of glycated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.6" spread="1.3"/>
                    <measurement group_id="B2" value="8.4" spread="2.4"/>
                    <measurement group_id="B3" value="8.0" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>DM duration</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22" spread="12.9"/>
                    <measurement group_id="B2" value="18.4" spread="6.4"/>
                    <measurement group_id="B3" value="20.2" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Time Spent in Hyperglycemia &gt; 180 mg/dL</title>
        <time_frame>Through study completion, during hospital stay, an average of 1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Continuous Glucose Monitoring and Point of Care Blood Glucose</title>
            <description>Hospitalized patients with Diabetes Mellitus type 2 (DM2) managed with Continuous glucose monitoring (CGM) and Point of Care (POC) Finger sticks blood glucose&#xD;
Continuous glucose Monitoring (CGM) device and Point of Care (POC) blood glucose: Testing Blood Glucose levels with Continuous glucose Monitoring (CGM) device and Point of Care (POC) blood glucose</description>
          </group>
          <group group_id="O2">
            <title>Point of Care (POC) Blood Glucose</title>
            <description>Hospitalized Diabetes Mellitus type 2 (DM2) patients managed with Point of Care (POC) blood glucose only&#xD;
Point of Care (POC) blood glucose: Testing Blood Glucose levels with Point of Care (POC) blood glucose</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Time Spent in Hyperglycemia &gt; 180 mg/dL</title>
          <units>percentage of time spent &gt; 180mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.47" spread="14.71"/>
                    <measurement group_id="O2" value="35.25" spread="29.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Time Spent in Significant Hyperglycemia (&gt;300 mg/dL)</title>
        <time_frame>Through study completion, during hospital stay, an average of 1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Continuous Glucose Monitoring and Point of Care Blood Glucose</title>
            <description>Hospitalized patients with Diabetes Mellitus type 2 (DM2) managed with Continuous glucose monitoring (CGM) and Point of Care (POC) Finger sticks blood glucose&#xD;
Continuous glucose Monitoring (CGM) device and Point of Care (POC) blood glucose: Testing Blood Glucose levels with Continuous glucose Monitoring (CGM) device and Point of Care (POC) blood glucose</description>
          </group>
          <group group_id="O2">
            <title>Point of Care (POC) Blood Glucose</title>
            <description>Hospitalized Diabetes Mellitus type 2 (DM2) patients managed with Point of Care (POC) blood glucose only&#xD;
Point of Care (POC) blood glucose: Testing Blood Glucose levels with Point of Care (POC) blood glucose</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Time Spent in Significant Hyperglycemia (&gt;300 mg/dL)</title>
          <units>percent of time spent &gt; 300mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.28" spread="5.65"/>
                    <measurement group_id="O2" value="5.52" spread="12.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Hypoglycemic Events (&lt; 70mg/dL)</title>
        <time_frame>Through study completion, during hospital stay, an average of 1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Continuous Glucose Monitoring and Point of Care Blood Glucose</title>
            <description>Hospitalized patients with Diabetes Mellitus type 2 (DM2) managed with Continuous glucose monitoring (CGM) and Point of Care (POC) Finger sticks blood glucose&#xD;
Continuous glucose Monitoring (CGM) device and Point of Care (POC) blood glucose: Testing Blood Glucose levels with Continuous glucose Monitoring (CGM) device and Point of Care (POC) blood glucose</description>
          </group>
          <group group_id="O2">
            <title>Point of Care (POC) Blood Glucose</title>
            <description>Hospitalized Diabetes Mellitus type 2 (DM2) patients managed with Point of Care (POC) blood glucose only&#xD;
Point of Care (POC) blood glucose: Testing Blood Glucose levels with Point of Care (POC) blood glucose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hypoglycemic Events (&lt; 70mg/dL)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events collected from the patient enrollment to the end of patient hospitalization, an average of 5 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Continuous Glucose Monitoring and Point of Care Blood Glucose</title>
          <description>Hospitalized patients with Diabetes Mellitus type 2 (DM2) managed with Continuous glucose monitoring (CGM) and Point of Care (POC) Finger sticks blood glucose&#xD;
Continuous glucose Monitoring (CGM) device and Point of Care (POC) blood glucose: Testing Blood Glucose levels with Continuous glucose Monitoring (CGM) device and Point of Care (POC) blood glucose</description>
        </group>
        <group group_id="E2">
          <title>Point of Care (POC) Blood Glucose</title>
          <description>Hospitalized Diabetes Mellitus type 2 (DM2) patients managed with Point of Care (POC) blood glucose only&#xD;
Point of Care (POC) blood glucose: Testing Blood Glucose levels with Point of Care (POC) blood glucose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding at site of the CGM insertion</sub_title>
                <description>Minor bleeding at the site of CGM insertion</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Transferred to ICU (for non study-related reasons)</sub_title>
                <description>Patient developed dry gangrene and was transferred to ICU related to osteomyelitis, not the CGM in our study.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ilias (Elias) Spanakis</name_or_title>
      <organization>Veterans Affairs Medical Center</organization>
      <phone>(617) 319-9731</phone>
      <email>ispanakis@som.umaryland.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

